Arthneeti
JP

Jubilant Pharmova Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Jubilant Pharmova Ltd Q3 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book

Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,064
Market cap₹17.0K Cr
P/E43.7
Updated24 Sept 2026
Read4 min read

Based on Jubilant Pharmova Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3’FY26 Total Income: Rs. Q3’FY26 Financials: - EBITDA: Rs.

From Jubilant Pharmova Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Q3’FY26 Total Income: Rs. 2,143 Cr., up from Rs. 1,831 Cr. in Q3’FY25 (approx. 17% YoY growth). - Major segments Q3’FY26 revenue with YoY change: • Radiopharma: Rs. 935 Cr. (vs. 841 Cr., ~11% YoY) • Allergy Immunotherapy: Rs. 193 Cr. (vs. 171 Cr., 12% YoY) • CDMO Sterile Injectables: Rs. 457 Cr. (vs. 306 Cr., 49% YoY) • CRDMO: Rs. 298 Cr. (vs. 292 Cr., 2% YoY) • Generics: Rs. 226 Cr. (vs. 200 Cr., 13% YoY) • Drug Discovery Services: Rs. 169 Cr. (vs. 150 Cr., 13% YoY) • CDMO API: Rs. 129 Cr. (vs. 142 Cr., -9% YoY) - Outlook: • Vision 2030 plans to double revenues by FY30 (~2x FY24 revenues).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Expansion at Greater Noida & Bengaluru sites; new site Devanahalli, Bengaluru: capacity increasing from 1,000 FTEs (FY25) to 2,000 (FY28) to 4,000 (FY30); Total Capex USD 150 Mn; expected RoCE > 20%.
  • New Isolator Fill & Finish Line (Line 5) at Montreal: construction started; Capex USD 114 Mn, concessional loan USD 35 Mn; production resumed Q4’FY26; technology transfer revenue expected FY29; target EBITDA breakeven FY28.
  • Line 4 installation (Spokane): on track; technology transfer revenue to start Q4’FY27; full utilization in 3.5 years; peak revenue potential USD 80-90 Mn.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • On Page 43, the presentation states: "Building a strong order book pipeline" for Line 4 installation.
  • It also mentions expectation of technology transfer revenues to start in Q4’FY27.
  • No specific figures on order book size, order inflow, or pending orders are provided in the presentation.

Jubilant Pharmova Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Jubilant Pharmova Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Morepen Laboratories Ltd (Q3 FY26)

    488 crores, up 17% from Q3 FY25 Rs. Key investor presentation takeaways from Morepen Laboratories Ltd's Q3 FY26 investor presentation — and how it ranks against

  • NGL Fine Chem Ltd (Q3 FY26)

    Quarterly Revenue (Q3FY26):** ₹127.51 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q3 FY26 investor presentation — and how it ranks aga

  • Shree Ganesh Remedies Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹21.11 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation — and how it rank

  • Anuh Pharma Ltd (Q3 FY26)

    Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key investor presentation takeaw

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Jubilant Pharmova Ltd Q3 FY26 results?

Q3’FY26 Total Income: Rs. Q3’FY26 Financials: - EBITDA: Rs.

What is Jubilant Pharmova Ltd share price analysis?

Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Pharmova Ltd planning capital expenditure?

Expansion at Greater Noida & Bengaluru sites; new site Devanahalli, Bengaluru: capacity increasing from 1,000 FTEs (FY25) to 2,000 (FY28) to 4,000 (FY30); Total Capex USD 150 Mn; expected RoCE > 20%.

Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.